Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers

• Published in: EBioMedicine Vol. 66; p. 103329
• Main Authors: Cui, Guanglin, Fan, Qingbo, Li, Zhenfeng, Goll, Rasmus, Florholmen, Jon
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.04.2021; Elsevier
• Subjects: Anti-TNF therapy; Biomarker; Crohn's disease; Inflammatory bowel disease; Review; Ulcerative colitis; Inflammatory bowel disease; Biomarker; Crohn's disease; Anti-TNF therapy; Ulcerative colitis
• ISSN: 2352-3964; 2352-3964
• DOI: 10.1016/j.ebiom.2021.103329

Neutralizing tumour necrosis factor (TNF) antibodies have been widely used to treat inflammatory bowel disease (IBD) in the clinical practice. In this review, the principal biomarker analysis revealed that faecal calprotectin, C-reactive protein, serum or mucosal concentrations of anti-TNF monoclonal antibodies (mAbs) and antibodies to anti-TNF mAbs are commonly used as current biomarkers in the evaluation of anti-TNF therapeutic efficacy. However, mucosal cytokine transcripts. microRNAs, proteomics and faecal and mucosal gut microbiota profile and mucosal histological features are reported to be novel candidates of biomarkers with high clinical utility in the evaluation of anti-TNF therapeutic efficacy in patients with IBD. Therefore, a robust validation of novel promising biomarkers and comparison studies between current used and novel biomarkers are urgently required to improve their value in the evaluation of therapeutic efficacy and optimization of personalized medicine and identification of IBD candidates for anti-TNF therapy in future clinical practice.